Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.
Author:
- C Lee VentolaCVC Lee Ventola
- 1 October 2015
- journal article
- Vol. 40 (10) , 680-9
Abstract
P&T committees will play a key role in driving the adoption of biosimilars, which have unique characteristics compared with small-molecule generic drugs. Key elements of formulary review will include clinical parameters, product characteristics, and institutional considerations, which are among the issues covered in this article.Keywords
This publication has 20 references indexed in Scilit:
- Biosimilar Competition In The United States: Statutory Incentives, Payers, And Pharmacy Benefit ManagersHealth Affairs, 2015
- Formulary Selection Criteria for Biosimilars: Considerations for US Health-System PharmacistsHospital Pharmacy, 2014
- Biosimilars: Implications for health-system pharmacistsAmerican Journal of Health-System Pharmacy, 2013
- Biosimilars: Company Strategies to Capture Value from the Biologics MarketPharmaceuticals, 2012
- Biosimilars might not measure up to health plan expectations.2012
- The State of the Art in the Development of BiosimilarsClinical Pharmacology & Therapeutics, 2012
- Biosimilars and market access: a question of comparability and costs?Targeted Oncology, 2012
- Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety.2012
- President obama reopens debate on patented biologics: will the FDA quickly define an abbreviated pathway for biosimilars?2011
- Challenges in the anticipation of biosimilars: how must a P&T committee gear up?2007